Fieldpoint Private Securities’s Corcept Therapeutics CORT Stock Holding History

Fieldpoint Private Securities’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$1K	Sell	60 -20	-25%	-$436	﹤0.01%	1309
2022 Q1	$2K	Sell	80 -75	-48%	-$1.59K	﹤0.01%	1465
2021 Q4	$3K	Sell	155 -80	-34%	-$1.62K	﹤0.01%	1386
2021 Q3	$5K	Sell	235 -220	-48%	-$4.6K	﹤0.01%	1251
2021 Q2	$10K	Sell	455 -70	-13%	-$1.56K	﹤0.01%	1009
2021 Q1	$12K	Buy	525 +85	+19%	+$2.27K	﹤0.01%	943
2020 Q4	$12K	Buy	+440	New	+$9.27K	﹤0.01%	841

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fieldpoint Private Securities's CORT Position: Q2 2022 in Review

Fieldpoint Private Securities reduced its Corcept Therapeutics (CORT) stake by 25% in Q2 2022, selling an estimated $436 and leaving 60 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #1309.

Fieldpoint Private Securities first reported a position in CORT in Q4 2020 and has held it in 7 quarters since. The position peaked at $12K in Q1 2021. 225 funds tracked by Wall St. Rank hold CORT as of Q2 2022.

Fieldpoint Private Securities held 60 shares of Corcept Therapeutics worth $1K as of Q2 2022.
Fieldpoint Private Securities sold 20 Corcept Therapeutics shares in Q2 2022, an estimated $436.
Corcept Therapeutics made up ﹤0.01% of Fieldpoint Private Securities's portfolio in Q2 2022, its #1309 holding.
Fieldpoint Private Securities first reported a position in Corcept Therapeutics in Q4 2020 and has held it in 7 quarters since.
Fieldpoint Private Securities's Corcept Therapeutics position peaked at $12K in Q1 2021.
225 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2022.

Based on Fieldpoint Private Securities's 13F filing for Q2 2022, filed 5 Aug 2022.